Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003007 · ClinicalTrials.gov registry record · Phase 2
Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma
A Phase 2 study, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00003007: Completed Phase 2 study, sponsored by University of Tennessee.
NCT00003007 is a Phase 2 study that has completed, run by University of Tennessee. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003007, a Phase 2 study, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to determine the effectiveness of giving interferon alfa after chemotherapy and peripheral stem cell transplantation to patients who have stage III or stage IV multiple myeloma and who have been treated with high-dose melphalan.
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG melphalan
- BIOLOGICAL recombinant interferon alfa
- BIOLOGICAL sargramostim
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-07 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
What the finished NCT00003007 record still lists
NCT00003007 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003007 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003007 about?
NCT00003007 is a clinical study titled "Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Interferon alfa may interfere with the growth of can...
What is the current status of trial NCT00003007?
This trial is currently completed. It is a Phase 2 study. The study started on 1996-07. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00003007?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), melphalan (DRUG), recombinant interferon alfa (BIOLOGICAL), sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003007?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia